Literature DB >> 12565178

Expression of p53R2, newly p53 target in oral normal epithelium, epithelial dysplasia and squamous cell carcinoma.

Souichi Yanamoto1, Goro Kawasaki, Izumi Yoshitomi, Akio Mizuno.   

Abstract

Recently, the p53R2 gene has been isolated and shown to play a crucial role in DNA repair after DNA damage. The p53R2 gene encodes the p53 inducible ribonucleotide reductase small subunit 2 homologue, which is part of the p53 pathway. However, the function of p53R2 in human cancer is still unclear. We investigated p53R2 mRNA expression in human oral normal epithelium, epithelial dysplasias and squamous cell carcinomas (SCCs). Surgical or biopsy-proven specimens of 10 normal epithelium, 48 epithelial dysplasias and 63 SCCs were collected in our department. Then, p53R2 was identified by in situ hybridization to visualize and localize the expression of specific mRNAs. The authors examined the p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism analysis. p53, mdm2, p21(WAF1/CIP1) and Ki-67 expression was detected by immunohistochemistry. p53R2 expression was detected in none of ten normal epithelium (0%), ten of 48 dysplasias (20.8%) and 33 of 63 SCCs (52.4%). In oral SCC, the expression of p53R2 was significantly associated with tumor size, lymph node metastasis and histological differentiation (P=0.014, 0.046 and 0.022, respectively). p53R2 expression was significantly associated with p53 abnormality in epithelial dysplasia and SCC (P=0.034 and 0.009, respectively). Of 63 patients, 37 received preoperative radiochemotherapy. p53R2 mRNA expression was significantly associated with the pathologic response to radiochemotherapy (P=0.031). This study suggested that p53R2 expression could be associated with oral carcinogenesis. The presence of p53R2 mRNA expression would be a predictive factor for tumor development, tumor cell differentiation and the sensitivity to radiochemotherapy in oral SCC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12565178     DOI: 10.1016/s0304-3835(02)00588-8

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  13 in total

1.  Reprimo 824 G>C and p53R2 4696 C>G single nucleotide polymorphisms and colorectal cancer: a case-control disease association study.

Authors:  William D Beasley; John Beynon; Gareth J S Jenkins; Jim M Parry
Journal:  Int J Colorectal Dis       Date:  2008-04       Impact factor: 2.571

Review 2.  Nucleotide metabolism, oncogene-induced senescence and cancer.

Authors:  Katherine M Aird; Rugang Zhang
Journal:  Cancer Lett       Date:  2014-01-29       Impact factor: 8.679

3.  Characteristics of benign lymphoadenosis of oral mucosa.

Authors:  Shu-Xia Li; Shi-Feng Yu; Kai-Hua Sun
Journal:  World J Gastroenterol       Date:  2005-08-07       Impact factor: 5.742

4.  p53R2 inhibits the proliferation of human cancer cells in association with cell-cycle arrest.

Authors:  Keqiang Zhang; Jun Wu; Xiwei Wu; Xiaochen Wang; Yan Wang; Ning Zhou; Mei-ling Kuo; Xiyong Liu; Bingsen Zhou; Lufen Chang; David Ann; Yun Yen
Journal:  Mol Cancer Ther       Date:  2011-01-07       Impact factor: 6.261

5.  Ribonucleotide reductase large subunit M1 plays a different role in the invasion and metastasis of papillary thyroid carcinoma and undifferentiated thyroid carcinoma.

Authors:  Zejun Fang; Rui Song; Chaoju Gong; Xiaomin Zhang; Guoping Ren; Jinfan Li; Yuexia Chen; Lanlan Qiu; Lingming Mei; Ronghui Zhang; Xueping Xiang; Xiang Chen; Jimin Shao
Journal:  Tumour Biol       Date:  2015-10-09

6.  Clofarabine Has Apoptotic Effect on T47D Breast Cancer Cell Line via P53R2 Gene Expression.

Authors:  Mohammad Rahmati-Yamchi; Nosratollah Zarghami; Hojjatollah Nozad Charoudeh; Yasin Ahmadi; Behzad Baradaran; Mohammad Khalaj-Kondori; Morteza Milani; Abolfazl Akbarzadeh; Maghsud Shaker; Mohammad Pourhassan-Moghaddam
Journal:  Adv Pharm Bull       Date:  2015-11-30

7.  Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk.

Authors:  Linda E Kelemen; Kathryn L Terry; Marc T Goodman; Penelope M Webb; Elisa V Bandera; Valerie McGuire; Mary Anne Rossing; Qinggang Wang; Ed Dicks; Jonathan P Tyrer; Honglin Song; Jolanta Kupryjanczyk; Agnieszka Dansonka-Mieszkowska; Joanna Plisiecka-Halasa; Agnieszka Timorek; Usha Menon; Aleksandra Gentry-Maharaj; Simon A Gayther; Susan J Ramus; Steven A Narod; Harvey A Risch; John R McLaughlin; Nadeem Siddiqui; Rosalind Glasspool; James Paul; Karen Carty; Jacek Gronwald; Jan Lubiński; Anna Jakubowska; Cezary Cybulski; Lambertus A Kiemeney; Leon F A G Massuger; Anne M van Altena; Katja K H Aben; Sara H Olson; Irene Orlow; Daniel W Cramer; Douglas A Levine; Maria Bisogna; Graham G Giles; Melissa C Southey; Fiona Bruinsma; Susanne K Kjaer; Estrid Høgdall; Allan Jensen; Claus K Høgdall; Lene Lundvall; Svend-Aage Engelholm; Florian Heitz; Andreas du Bois; Philipp Harter; Ira Schwaab; Ralf Butzow; Heli Nevanlinna; Liisa M Pelttari; Arto Leminen; Pamela J Thompson; Galina Lurie; Lynne R Wilkens; Diether Lambrechts; Els Van Nieuwenhuysen; Sandrina Lambrechts; Ignace Vergote; Jonathan Beesley; Peter A Fasching; Matthias W Beckmann; Alexander Hein; Arif B Ekici; Jennifer A Doherty; Anna H Wu; Celeste L Pearce; Malcolm C Pike; Daniel Stram; Jenny Chang-Claude; Anja Rudolph; Thilo Dörk; Matthias Dürst; Peter Hillemanns; Ingo B Runnebaum; Natalia Bogdanova; Natalia Antonenkova; Kunle Odunsi; Robert P Edwards; Joseph L Kelley; Francesmary Modugno; Roberta B Ness; Beth Y Karlan; Christine Walsh; Jenny Lester; Sandra Orsulic; Brooke L Fridley; Robert A Vierkant; Julie M Cunningham; Xifeng Wu; Karen Lu; Dong Liang; Michelle A T Hildebrandt; Rachel Palmieri Weber; Edwin S Iversen; Shelley S Tworoger; Elizabeth M Poole; Helga B Salvesen; Camilla Krakstad; Line Bjorge; Ingvild L Tangen; Tanja Pejovic; Yukie Bean; Melissa Kellar; Nicolas Wentzensen; Louise A Brinton; Jolanta Lissowska; Montserrat Garcia-Closas; Ian G Campbell; Diana Eccles; Alice S Whittemore; Weiva Sieh; Joseph H Rothstein; Hoda Anton-Culver; Argyrios Ziogas; Catherine M Phelan; Kirsten B Moysich; Ellen L Goode; Joellen M Schildkraut; Andrew Berchuck; Paul D P Pharoah; Thomas A Sellers; Angela Brooks-Wilson; Linda S Cook; Nhu D Le
Journal:  Mol Nutr Food Res       Date:  2014-07-28       Impact factor: 5.914

8.  RRM2B-Mediated Regulation of Mitochondrial Activity and Inflammation under Oxidative Stress.

Authors:  Er-Chieh Cho; Mei-Ling Kuo; Jia-Hui Cheng; Yu-Chi Cheng; Yi-Chen Hsieh; Yun-Ru Liu; Rong-Hong Hsieh; Yun Yen
Journal:  Mediators Inflamm       Date:  2015-05-18       Impact factor: 4.711

9.  Tumor suppressor FOXO3 regulates ribonucleotide reductase subunit RRM2B and impacts on survival of cancer patients.

Authors:  Er-Chieh Cho; Mei-Ling Kuo; Xiyong Liu; Lixin Yang; Yi-Chen Hsieh; Jinghan Wang; Yawen Cheng; Yun Yen
Journal:  Oncotarget       Date:  2014-07-15

10.  Overexpression of p53R2 is associated with poor prognosis in lung sarcomatoid carcinoma.

Authors:  Jiewei Chen; Yongbo Xiao; Xiaoyan Cai; Jun Liu; Keming Chen; Xinke Zhang
Journal:  BMC Cancer       Date:  2017-12-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.